Weight loss therapeutics Market, Size, Share, Growth, Trends, Insight and Industry Forecast, 2021-2028

Global Weight loss therapeutics Market is segmented By Approved Drug Formulations (Liraglutide, Buproprion and naltrexone, Lorcaserin, Phentermine and topiramate), By Distribution Channels (Hospitals , Specialized Clinics, Retail Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

Market Overview

The Weight loss therapeutics Market The size was valued at US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028). 

Weight loss therapy is a form of cognitive-behavioral therapy (CBT), an approach to psychotherapy used to treat a multitude of issues.

Source: DataM Intelligence Analysis (2020)

Market Dynamics

An increase in the incidence of health problems such as diabetes, cardiovascular disease, and cancer will drive the market. The change in food habits and lifestyle will also drive the market in the forecast period.

An increase in the incidence of health problems such as diabetes, cardiovascular disease, and cancer will drive the market

Obesity is serious health issue because it is associated with poor mental health outcomes and reduced quality of life. It is also associated with the leading causes of death in the United States and worldwide, including diabetes, heart disease, stroke, and some types of cancer. Extra weight makes one more likely to have high blood pressure, high cholesterol. Both of these conditions make heart disease or stroke more likely. A small amount of weight loss can reduce the chances of developing heart disease or a stroke. Around 8 out of 10 people with type 2 diabetes are overweight or have obesity. Over time, high blood glucose leads to heart disease, stroke, kidney disease, eye problems, nerve damage, and other health problems.

Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD). According to a Journal of the American College of Cardiology, the number of people dying from cardiovascular disease (CVD) is steadily rising, including one-third of all deaths globally in 2019. The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structure.

The change in food habits and lifestyle will also drive the market in the forecast period

In studies where people freely choose what they eat, there may be some benefits to a higher protein, lower carbohydrate approach. For chronic disease prevention, though, these nutrients' quality and food sources matter more than their relative quantity in the diet. And the latest Hospitals suggests that the same diet quality message applies to weight control. Over the past 30 years in the U.S., the percentage of calories from fat in people's diets has gone down, but obesity rates have skyrocketed.

Changes in the lifestyle remain the mainstay of treatment and are important for the long-term maintenance of weight loss. In Australia the increased rates of overweight and obesity are part of a worldwide trend. Today, over 50% of women, up to 75% of males, and approximately 25% of children and adolescents are classified as overweight or obese. The environment and changing lifestyles certainly play significant role as high energy foods have become readily available, and it is no longer essential to engage in physical activity. As a result, obesity and its health problems have become all too common in Australian individuals.

Limited efficiency of the available drugs, high cost, and the side effects associated will hamper the market

Due to the risk of other side effects and dependence stimulant-type weight loss medications like diethylpropion or phentermine are only recommended for short-term use (up to 12 weeks). However, for longer-term weight loss orlistat (Alli, Xenical) can be used including the maintenance of previously lost weight. One can also get Alli at the drugstore without a prescription. Prescription weight-loss drugs used for chronic, long-term weight loss are bupropion and naltrexone (Contrave), phentermine and topiramate (Qsymia) and liraglutide (Saxenda) but only if adequate results are seen. Incase 3% to 4% weight loss has not been achieved after 12 to 16 weeks, long-term treatment is typically stopped. Weight loss medications are used alongside a low-calorie diet, a doctor-approved exercise plan for best results. However, people might regain some weight they lost when they stop using weight loss drugs unless diet and exercise are continued. Some people can't reach their weight loss goals with intensive behavioral therapy alone. They have other things that contribute to their weight issues. These can include hormone problems or a  genetically related weight problems.

COVID-19 Impact Analysis

COVID-19 had a negative impact on the Weight loss therapeutics Market With the demand for COVID-19 vaccines, the demand for the weight loss therapeutics market has decreased. But with the government lifting the bans and industries opening up their manufacturing units, the weight loss therapeutics market will increase.

Segment Analysis

Liraglutide will drive the weight loss therapeutics market

In a population of obese patients, liraglutide is effective at inducing and sustaining weight loss including those patients with hypertension, dyslipidemia, type 2 diabetes, and obstructive sleep apnea. It is sold under the brand name Victoza among others, liraglutide is an anti-diabetic medication used to treat type 2 diabetes, obesity, and chronic weight management.

For chronic weight management the U.S. FDA has approved a supplemental indication for Saxenda (liraglutide) among pediatric patients aged 12 and above who are obese, as defined by specific body mass index (BMI). To a reduced-calorie diet and greater physical activity Saxenda is an adjunct (additional therapy). To induce and sustain weight loss Liraglutide helps in patients with obesity. The drug offers unique benefit of improved glycemic control.

The hospitals segment will dominate the weight loss therapeutics market

Obesity is a major drive in the development of diabetes and cardiovascular disease. Weight reduction and maintenance are key therapeutic goals in both the management of obesity and its associated comorbidities, type 2 diabetes in particular. Unfortunately, several weight loss induced hormonal changes to encourage weight regain and counteract maintained weight loss. In selecting the best anti-obesity drug for a specific patient, the aspects of side effects, contraindications, and drug interactions should be kept in mind. Additionally, health care practitioners should consider the weight effects of pharmacotherapy in the management of obesity-related comorbidities and consider weight-neutral or weight-reducing medications that can complement the patient's desire for a healthier lifestyle. It requires proper guidance and care, which is available in hospitals. Hospitals provide the best medical practitioner who can guide the patient with proper weight loss therapeutics considering requirements. Hence, this segment will dominate the market.

Geographical Analysis

North America region will dominate the weight loss therapeutics market

Approximately two out of three U.S. adults are obese or overweight (69%), and one out of three are obese (36%). NHANES show that 39.6% of adults, 18.5 % of children ages 2 to 19 in America have obesity. The State of Obesity report noted that "these are the highest rates ever documented by NHANES.

Approximately 70% of American adults are obese or overweight. Being obese or overweight is a serious health issue associated with some leading causes of death, including heart disease, stroke,diabetes and it is also linked with an increased risk of certain type of cancer. For chronic weight management in adults with overweight or obesity, the U.S. FDA approved Wegovy (semaglutide) injection (2.4 mg once weekly) with at least one weight-related condition in addition to a reduced-calorie diet and increased physical activity.

Source: DataM Intelligence Analysis (2020)

Competitive Landscape

Major Key Players in the weight loss therapeutics market are Sanofi-Aventis, Abbott Laboratories, Novo Nordisk A/S, Arena Specialized Clinics GmbH, Orexigen Therapeutics, Inc., Johnson & Johnson Inc., Pfizer Inc., Novartis International AG, Biocon Ltd., VIVUS, Inc., China Resources Pharmaceutical GroupCo., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.

Novo Nordisk A/S

Overview: With 95 years of innovation and leadership,  Novo Nordisk is a global healthcare company in diabetes care. This heritage has given experience and capabilities that also enable them to help people defeat hemophilia, obesity, growth disorders, and other serious chronic diseases.

Product Portfolio: Novo Nordisk manufactures and markets Specialized Clinics products and services, specifically diabetes care medications and devices. Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.

Key Development: On June 4th, 2021,  Novo Nordisk A/S gained U.S. approval for its therapy that helped patients lose about 15% of body weight on average in trials. It is an alternative to an existing treatment from the Danish drugmaker as well as invasive, costly obesity surgery. The first weight management drug Wegovy is approved for chronic use in most obese and overweight adults in several years.

Why Purchase the Report?

• Visualize the composition of the weight loss therapeutics market Segmentation By Approved Drug Formulations and By Distribution Channels facility highlighting the key commercial assets and players.
• Identify commercial opportunities in weight loss therapeutics market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of weight loss therapeutics market- level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The weight loss therapeutics market report would provide an access to an approx. 52 market data table, 42  figures and 200 pages. 

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Hospitals Institutes
• Hospitals Professionals
• Emerging Companies
• Manufacturers

Market Segmentation

Weight loss therapeutics Market- By Approved Drug Formulations

• Liraglutide
• Buproprion and naltrexone
• Lorcaserin
• Phentermine and topiramate

Weight loss therapeutics Market- By Distribution Channels

• Hospitals
• Specialized Clinics
• Retail Pharmacies

Weight loss therapeutics Market- By Region

• North America
• Europe
• South America
• Asia Pacific
• Middle East and Africa

Table of Contents

1. Weight loss therapeutics MarketMethodology and Scope

   1. Hospitals Methodology
   2. Hospitals Objective and Scope of the Report

2. Weight loss therapeutics Market– Market Definition and Overview

3. Weight loss therapeutics Market– Executive Summary

   1. Market Snippet By Approved Drug Formulations
   2. Market Snippet By Distribution Channels

4. Weight loss therapeutics Market– Market Dynamics

   1. Market Impacting Factors
      1. Drivers
         1. An increase in the incidence of health problems such as diabetes, cardiovascular disease, and cancer will drive the market
         2. The change in food habits and lifestyle will also drive the market in the forecast period
      2. Restraints:
         1. Limited efficiency of the drugs, high cost, and the side effects associated will hamper the market
      3. Opportunity
      4. Impact Analysis

5. Weight loss therapeutics Market– Industry Analysis

   1. Porter's Five Forces Analysis
   2. Epidemiology Analysis
   3. Supply Chain Analysis
   4. Pricing Analysis
   5. Regulatory Analysis
   6. Reimbursement Analysis
   7. Unmet Needs

6. Weight loss therapeutics Market– COVID-19 Analysis

   1. Analysis of Covid-19 on the Market
      1. Before COVID-19 Market Scenario
      2. Present COVID-19 Market Scenario
      3. After COVID-19 or Future Scenario
   2. Pricing Dynamics Amid Covid-19
   3. Demand-Supply Spectrum
   4. Government Initiatives Related to the Market During Pandemic
   5. Manufacturers Strategic Initiatives
   6. Conclusion 

7. Weight loss therapeutics Market– By Approved Drug Formulations

   1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Approved Drug Formulations Segment
      2. Market Attractiveness Index, By Approved Drug Formulations Segment
   2. Liraglutide*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
   3. Buproprion and naltrexone
   4. Lorcaserin
   5. Phentermine and topiramate

8. Weight loss therapeutics Market– By Distribution Channels

   1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment
      2. Market Attractiveness Index, By Distribution Channels Segment
   2. Hospitals *
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
   3. Specialized Clinics
   4. Retail Pharmacies

9. Weight loss therapeutics Market– By Region

   1. Introduction
      1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
      2. Market Attractiveness Index, By Region
   2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Approved Drug Formulations
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
         1. U.S.
         2. Canada
         3. Mexico
   3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Approved Drug Formulations
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
         1. Germany
         2. U.K.
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
   4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Approved Drug Formulations
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
         1. Brazil
         2. Argentina
         3. Rest of South America
   5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Approved Drug Formulations
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
         1. China
         2. India
         3. Japan
         4. Australia
         5. Rest of Asia Pacific
   6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Approved Drug Formulations
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels

10. Weight loss therapeutics Market– Competitive Landscape

    1. Key Developments and Strategies
    2. Company Share Analysis
    3. Product Benchmarking
    4. List of Key Companies to Watch
    5. List of Company with disruptive technology
    6. List of Start Up Companies

11. Weight loss therapeutics Market- Company Profiles

    1. Novo Nordisk A/S*
       1. Company Overview
       2. Product Portfolio and Description
       3. Key Highlights
       4. Financial Overview
    2. Sanofi-Aventis
    3. ABBOTT LABORATORIES
    4. ARENA SPECIALIZED CLINICSS GMBH
    5. Orexigen Therapeutics, Inc.
    6. Johnson & Johnson Inc.
    7. Pfizer Inc.
    8. Novartis International AG
    9. CHINA RESOURCES PHARMACEUTICAL GROUPCO., LTD.
    10. Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.(LIST NOT EXHAUSTIVE)

12. Weight loss therapeutics Market– DataM  

    1. Appendix
    2. About Us and Services
    3. Contact Us